NEO · NeoGenomics, Inc.

The thesis

NeoGenomics' cancer-testing turnaround is ahead of its numbers, and the shares have moved the other way. The company pre-announced third-quarter revenue of about $209 million on 5 October 2026, above consensus, and said it will raise its full-year revenue guide midpoint. The shares then fell on a chief executive handover and kept falling to $16.02 by 8 October 2026. The third-quarter report, listed by MarketBeat for 27 October 2026 at 8:30 a.m. ET, settles whether revenue per test held and how large the raise is.

The 5 October 2026 8-K put preliminary, unaudited third-quarter revenue at about $209 million. Next-generation sequencing (NGS) revenue grew about 28% year over year, up from 26% in the second quarter. Investing.com put the consensus revenue estimate at $205.89 million that day. MarketBeat's current consensus is $206.60 million in revenue and $0.06 in earnings per share. The full-year guide of $802–806 million was reiterated, with the raise promised on the call.

The narrative is maturing: the turnaround is well covered after three brokers raised targets on 6 October 2026, yet the shares slid further after those raises rather than recovering. The adjusted close of $16.02 on 8 October 2026 sits 19.5% below the $19.91 52-week high. The 14-day relative strength index (RSI) is 28.6, an oversold reading. In this view, the decline prices leadership risk that a planned, internal succession does not justify. A report without a guide raise would prove that view wrong.

Bullish and bearish views on NeoGenomics, Inc.

The bull case on NeoGenomics, Inc. (NEO), in brief: The quarter beat before it was reported. The bear case: Leadership is changing on several fronts.

Bull case

• The quarter beat before it was reported. Preliminary third-quarter revenue was about $209 million, against a $205.89 million consensus cited by Investing.com on 5 October 2026. Second-quarter revenue was about $202 million.
• Sequencing growth sped up. NGS revenue grew about 28% year over year in the third quarter, up from 26% in the quarter reported on 28 July 2026 (5 October 2026 8-K). Higher-value tests keep gaining share of the mix.
• A guidance raise is already flagged. On 5 October 2026 the company said it expects to raise its full-year revenue guidance midpoint on the third-quarter call. The current guide is $802–806 million in revenue and $56–58 million in adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation).
• Brokers raised targets into the drop. On 6 October 2026, according to Benzinga, BTIG upgraded the shares to Buy with a $28 target, Needham raised its target to $22 and StoneX raised its target to $20. All three sit above the $16.02 close on 8 October 2026.
• Medicare coverage keeps widening. On 26 August 2026 RaDaR ST, the company's test for molecular residual disease (MRD), the cancer cells left after treatment, won Medicare coverage for immunotherapy response monitoring. That was its third covered use, with two more submissions pending at MolDX, the Medicare programme that reviews molecular tests.

Bear case

• Leadership is changing on several fronts. President and chief operating officer Warren Stone becomes chief executive on 4 January 2027, Tony Zook moves to executive chair, and Lynn Tetrault leaves the chair (5 October 2026 8-K). General Counsel Alicia Olivo's departure was set earlier for 2 October 2026.
• Growth leans on price per test. Second-quarter average revenue per test was $515, up 11.7% year over year, while clinical test volume grew 1.9% (28 July 2026 release). The July outlook assumed third-quarter volume growth near 1.5%.
• GAAP profit is not yet in sight. The 2026 guide calls for a GAAP net loss of $34–42 million. The company frames profitability on adjusted EBITDA of $56–58 million, a thin margin on about $800 million of revenue.
• Pharma services is shrinking. Non-clinical revenue fell 26% year over year in the second quarter, and the line is guided down high single digits for 2026.
• The shares keep falling on good news. The close went from $18.36 on 30 September 2026 to $16.50 on 6 October 2026 and $16.02 on 8 October 2026, despite a revenue beat and three target raises.

Price setup

The adjusted close was $16.02 on 8 October 2026. That is 19.5% below the $19.91 52-week high and 13.5% above the level three months earlier. The 14-day RSI of 28.6 is below the 30 line usually read as oversold, down from 37.2 on 6 October 2026.

Two levels come from the June 2026 convertible notes: $316 million at 0.75%, due 2032. The conversion price is $14.16 per share, and the capped call, a hedge the company bought, tops out at $20.98. The $14.16 conversion price is the line under the current price that defines the downside case here.

Crowding is light on the evidence available. No heavy retail attention, insider selling or new share issuance has been reported since the 5 October 2026 announcement. The main crowding factor is timing: the third-quarter report falls about 13 trading days after the last close.

Catalysts, next 30 days

• ~27 October 2026 (est.) — Third-quarter 2026 results and call. MarketBeat lists the date with an 8:30 a.m. ET call; the company had not issued a date release as of 9 October 2026. The report sets the size of the guide raise and shows whether revenue per test held near $515.
• ~13 October 2026 (est.) — Earnings-date announcement. The company usually confirms the report date in a press release about two weeks ahead.
• Q4 2026, no announced date — MolDX decisions on two RaDaR ST submissions. Each approval widens reimbursed MRD testing; a delay pushes the MRD ramp into 2027.
• 4 January 2027 — Warren Stone becomes chief executive. A handover with no further senior exits removes the overhang that drove the 6 October 2026 decline.

What would change the view

The case breaks if the third-quarter report raises nothing. A full-year revenue guide with no higher midpoint than $802–806 million, average revenue per test below $515, or an adjusted EBITDA guide cut below $56 million would each show the turnaround slowing. Further senior departures before 4 January 2027 would weaken the view that the succession is orderly.

On price, a daily close below $14.16, the conversion price of the 2032 notes, would show the market rejecting the case regardless of the report. A raise that lifts the midpoint and a recovery toward the $18.36 close of 30 September 2026 would show the leadership discount fading.

What it trades with

The shares trade with US cancer diagnostics peers on Medicare reimbursement news, since MolDX coverage and Medicare rates set pricing for much of the test menu. RaDaR ST competes in MRD testing, so coverage decisions for rival MRD tests move sentiment around that part of the business. The convertible notes tie part of the trading to two fixed levels, the $14.16 conversion price and the $20.98 capped-call ceiling.